Cover Image


Technologies Driving Precision Medicine

出版商 Frost & Sullivan 商品編碼 572937
出版日期 內容資訊 英文 47 Pages
商品交期: 最快1-2個工作天內
Back to Top
促進精密醫學的技術 Technologies Driving Precision Medicine
出版日期: 2017年09月26日 內容資訊: 英文 47 Pages


第1章 執行摘要

第2章 嵌合抗原受體T細胞(CAR-T細胞)療法

  • CAR-T細胞療法有望改變世界免疫療法的現狀
  • CAR-T細胞療法的效果可獲改善,但不良反應的改善仍懸而未決
  • 抗原鑑定及改善臨床反應是促進技術發展的主要要素
  • 主要的技術抑制要素包含了重要不良反應及實體腫瘤的效果

第3章 研究、資金、臨床和 IP 情況分析

  • CAR-T細胞療法的整體研究獲得高度關注
  • NIH投資的CAR-T細胞療法專案中癌症形成了主要應用程式領域
  • 中國在臨床實驗現狀領先全球,包含CAR-T細胞
  • 中國在CAR-T細胞的基礎革新,其專利情況領先全球

第4章 CAR-T細胞療法發展趨勢及未來展望

  • 實體腫瘤與血液腫瘤的CAR-T平臺比較分析
  • 應用CAR-T技術進行免疫療法的轉化
  • 主要CAR-T革新的概述
  • CAR-T平臺的未來

第5章 雙重特異性抗體/多重特異性抗體的新興技術情況

  • 雙重特異性抗體/多重特異性抗體的平台開發改善治療應用程式
  • 雙重特異性抗體/多重特異性抗體的平台改善了治療效果
  • 新的抗體平台改善了治療效果
  • 免疫毒性的不安點抑制了雙重特異性抗體/多重特異性抗體平台開發

第6章 研究、資金、臨床和 IP 情況分析

  • 雙重特異性抗體/平台的研究趨勢擴大
  • 癌症是雙重特異性抗體/多重特異性抗體相關NIH專案的主要投資領域
  • 雙重特異性抗體/多重特異性抗體的大多數臨床研究都還在早期階段
  • 美國在雙重特異性抗體/多重特異性抗體平台革新的IP現狀處於領先地位

第7章 雙重特異性抗體/多重特異性抗體的整體產業發展

  • 雙重特異性抗體療法平台超越了傳統單劑治療
  • 雙重特異性抗體療法的主要創新者
  • 雙重特異性抗體/多重特異性抗體的主要創新者

第8章 成長機會、企業動態

  • 成長機會 1: 分子分析平臺
  • 成長機會 2: CAR-T細胞療法
  • 成長機會 3: 雙重特異性抗體/多重特異性抗體
  • 成功和成長的戰略要務

第9章 附錄

Product Code: D7CB

Emerging Role of Chimeric Antigen Receptor (CAR) T-cell Treatment and Bispecific/Multi-specific T-cell Engaging Antibody Therapies

Targeted and personalized therapeutics are likely to transform the existing precision medicine landscape. With recent landmark regulatory approval, CAR T therapy has the potential to emerge as the industry standard for cancer management in the future and potentially replace existing treatment techniques. Bispecific and multi-specific antibody platforms are likely to emerge as the preferred alternatives for existing monotherapy strategies as they offer increased therapeutic efficacy, while reducing off-target effects.

This global research service provides comprehensive insights across key technologies, research trends, funding IP outlook, clinical trials and industry innovations that are likely to transform the landscape of chimeric antigen receptor (CAR) T cell and bispecific/multi-specific T cell engaging immunotherapies.

Table of Contents

1.0 Executive Summary

  • 1.1 Research Scope
  • 1.2 Research Methodology
  • 1.2 Research Methodology (Continued)
  • 1.3 Key Findings

2.0 Technologies Driving CAR T-cell Therapy

  • 2.1 CAR T-cell Therapies Ideally Poised to Transform the Global Immunotherapy Landscape
  • 2.2 CART Therapy Enables Improved Efficacy, Although Adverse Events May Continue to be a Cause For Concern
  • 2.3 Antigen Identification and Enhanced Clinical Response are the Key Technology Drivers
  • 2.4 Key Technology Restraints Comprise Critical Adverse Events and Reduced Efficacy in Solid Tumors

3.0 Analysis of Research, Funding, Clinical, and IP Landscapes

  • 3.1 CAR T-cell Therapy Garners Growing Attention Across Research
  • 3.2 Cancer Constitutes the Top Application Area For NIH-funded CAR T Therapy Projects
  • 3.3 China Leads Global Clinical Trial Landscape Involving CAR T-cells
  • 3.4 China Leads the Global Patent Landscape For CAR T-cell-based Innovations

4.0 Industry Trends and Future Perspectives for CAR T Therapies

  • 4.1 Comparative Analysis of CAR T Platforms in Solid and Hematological Cancers
  • 4.2 Transforming Immunotherapy With CAR T Technologies
  • 4.3 Overview of Key CAR T Innovators
  • 4.4 Future of CAR T Platform

5.0 Emerging Technological Landscape For Bispecific/Multi-specific Antibodies

  • 5.1 Development of Bispecific/Multi-specific Antibody Platforms For Enhanced Therapeutic Applications
  • 5.2 Bispecific/Multi-specific Platforms Offer Enhanced Therapeutic Benefits
  • 5.3 Novel Antibody Platforms Improve Treatment Efficacy
  • 5.4 Immunotoxicity Concerns Limit the Development of Bispecific/Multi-specific Antibody Platforms

6.0 Analysis of Research, Funding, Clinical, and IP Landscape

  • 6.1 Growing Research Trends in Bispecific Antibody Platforms
  • 6.2 Cancer is the Top Funding Area For NIH Projects Related to Bispecific/Multi-specific Therapeutic Antibodies
  • 6.3 Most Clinical Studies For Bispecific/Multi-specific Antibodies Are Still in Early Phase
  • 6.4 US Leads the IP Landscape For Innovations in Bispecific/Multi-specific Platforms

7.0 Industry Developments Across Bispecific and Multi-specific Antibody Therapeutics

  • 7.1 Bispecific Antibody Treatment Platforms Score Over Conventional Monotherapies
  • 7.2 Key Innovators Across Bispecific Therapies
  • 7.3 Key Innovators Across Bispecific and Multi-specific Therapies

8.0 Growth Opportunities and Companies to Action

  • 8.1 Growth Opportunity 1: Molecular Profiling Platforms
  • 8.2 Growth Opportunity 2: CAR T-cell Therapy
  • 8.3 Growth Opportunity 3: Bispecific/Multi-specific Antibodies
  • 8.4 Strategic Imperatives for Success and Growth

9.0 Appendix

  • 9.1 Summary of Key Contacts
  • 9.1 Summary of Key Contacts (continued)
  • Legal Disclaimer
Back to Top